Third Quarter & Recent Corporate Highlights
Middle East, NuroMENA, the UAE-based subsidiary, advanced its regional partnerships by appointing His Highness Sheikh Nahyan bin Zayed Al Nahyan as Executive Chairman, signing a Master Services Agreement with M42's IROS, and completing ADGM incorporation. The company also progressed a $50 million strategic partnership with Quazar Investment, strengthening Abu Dhabi–US collaboration in brain cancer treatment.
Non-Dilutive NIH Funding, Awarded $2.5 million in STTR grants to advance NEO212 for gliomas and leukemia, underscoring strong scientific validation and external funding support.
Technology Expansion, Executed an agreement to acquire an Advanced AI and 3D Bioprinting IP.
Media & Market Visibility
Featured on Fox Business, Bloomberg Television
Interviewed on Yahoo Finance's Trader Talk podcast discussing AI and biotech's role in brain cancer treatment.
Entered a 12-part national TV and media campaign with New to The Street, including commercials, earned media, and billboards.
Interviewed live by Kenny Polcari
Index Inclusion, Joined the Russell Microcap® Index, broadening exposure to institutional investors.
Strong IP Protection, Global patent portfolio spans all major pharmaceutical markets, covering the company's core CNS oncology assets.
Executive Leadership, Appointed Amir Heshmatpour as Chief Executive Officer to Drive Next Phase of Clinical and Corporate Growth
Scientific Leadership - Appointed leading neuro-oncologists Dr. David M. Ashley (Duke University), Dr. Alexandra M. Miller (NYU Langone Health), and Dr. Henry S. Friedman to its Scientific Advisory Board
Clinical Pipeline Progress
NEO100-01, Intranasal therapy for malignant recurrent WHO Grade 3 /4 IDH1 Astrocytoma
Announced Phase 2a clinical results for NEO100 in recurrent brain cancer, showing a 21% response rate vs. <8% historical average
44% of patients achieved six-month progression-free survival vs. 21-31% in historical datasets
33% remained alive ≥18 months after initiation of NEO100, demonstrating long term survival
No significant toxicity ...
